NCT01141439View on ClinicalTrials.gov

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

CompletedOBSERVATIONAL
Enrollment

815,377

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

June 30, 2007

Study Completion Date

July 31, 2010

Conditions
Asthma
Interventions
DRUG

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

Initiation of HFA-BDP (any dose) in steroid naive patients via MDI

DRUG

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI

DRUG

Fluticasone propionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI

DRUG

Beclomethasone dipropionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI

DRUG

fluticasone propionate

Initiation of FP (any dose) via MDI in steroid naive patient

DRUG

Chlorofluorocarbon beclomethasone dipropionate

Initiation of CFC-BDP (any dose) via MDI in steroid naive patient

Trial Locations (1)

SW8 5NQ

General Practice Research Database, London

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

Research in Real-Life Ltd

NETWORK

NCT01141439 - Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management | Biotech Hunter | Biotech Hunter